The tissue diagnostics market is expected to witness expansion at 7 percent CAGR by 2018. Tissue diagnostics are primarily used to monitor, diagnose and manage cancer. This market consists of reagents, kits and instruments and is involved in the treatment of the disease.
For Market Research Report on ÂTissue Diagnostics MarketÂ Visit Â http://www.grandviewresearch.com/industry-analysis/tissue-diagnostics-market
The key factors driving the tissue diagnostics market are increasing incidences of cancer, rapidly increasing aged population and use of personalized medicines for cancer. However, stringent regulatory frameworks and lack of budget reimbursement are likely to hamper the market over the coming years. The tissue diagnostics market can be fragmented into five major categories, including products, technologies, diseases, consumers and geographies.
The market, on the basis of products, can be segmented into instruments and consumables. The tissue diagnostics market, on the basis of technologies, includes ISH (in situ hybridization), digital pathology & workflow management and IHC (immunohistochemistry). IHC captured major share as a result of its rising use in developing personalized medicines. The tissue diagnostics market, on the basis of diseases, can be segregated into lymphoma, gastric cancer, breast cancer, NSCLC (non-small cell lung carcinoma) and prostate cancer. Breast cancer, due to rising incidences, holds the largest market share. The consumers market includes research laboratories, CRO (contract research organizations), pharmaceuticals and hospitals.
Geographically, the tissue diagnostics market is divided into four key regions, including, North America, Europe, Asia Pacific and ROW (rest of the world). North America dominated the market in terms of revenue. This was on account of advanced technologies, improved healthcare infrastructure and patient awareness in the region.
Information Source: Grand View Research